Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study

World Journal of Gastroenterology

Volumn 21, Issue 18, 2015, Pages 5647-5653

  Terrier, Benjamin ^a,b   Lapidus, Nathanael ^a,c,d   Pol, Stanislas ^b   Serfaty, Lawrence ^d   Ratziu, Vlad ^e   Asselah, Tarik ^f   Thibault, Vincent ^e   Souberbielle, Jean Claude ^g   Carrat, Fabrice ^a,c,d   Cacoub, Patrice ^a,e,h,i  

^a SORBONNE UNIVERSITÉ   (France)

^b Paris 5 ^*  (France)

^c INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f BEAUJON HOSPITAL   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Unit of Dermatology   (France)

ⁱ CNRS   (France)

Author keywords

Chronic hepatitis; Hepatitis C virus; Pegylated interferon; Ribavirin; Vitamin D

Indexed keywords

COLECALCIFEROL; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; VITAMIN D; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CALCIFEDIOL; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; VITAMIN;

ADULT; AGED; ANTIVIRAL THERAPY; BLOOD SAMPLING; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VITAMIN D DEFICIENCY; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; FRANCE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; CALCIFEDIOL; CHOLECALCIFEROL; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTENTION TO TREAT ANALYSIS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84929192424     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i18.5647     Document Type: Review

References (17)

1. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303 [PMID: 20375406 doi: 10.1056/NEJMoa0908014]
2. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 528-540 [PMID: 19380853 doi: 10.7326/0003-4819-150-8-200904210-00007]
3. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838 [PMID: 19403902 doi: 10.1056/NEJMoa0806104]
4. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliére M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850 [PMID: 19403903 doi: 10.1056/NEJMoa0807650]
5. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
6. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 doi: 10.1056/NEJMoa1009482]
7. Asselah T. Triple therapy with boceprevir or telaprevir for prior HCV non-responders. Best Pract Res Clin Gastroenterol 2012; 26: 455-462 [PMID: 23199504 doi: 10.1016/j.bpg.2012.09.003]
8. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-523 [PMID: 24209977 doi: 10.1016/S0140-6736(13)62121-2]
9. Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, Licata G, Porcasi R, Marchesini G, Craxí A. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-1167 [PMID: 20162613 doi: 10.1002/hep.23489]
10. Terrier B, Jehan F, Munteanu M, Geri G, Saadoun D, Séne D, Poynard T, Souberbielle JC, Cacoub P. Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. Rheumatology (Oxford) 2012; 51: 2083-2090 [PMID: 22908327 doi: 10.1093/rheumatology/kes209]
11. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol 2011; 17: 5184-5190 [PMID: 22215943 DOI: 10.3748/wjg.v17.i47.5184]
12. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourliére M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-441 [PMID: 23669289 doi: 10.1016/j.jhep.2013.04.035]
13. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293 [PMID: 8690394]
14. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075 [PMID: 11297957]
15. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 1993; 39: 529-533 [PMID: 8448871]
16. Von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11: 344-349 [PMID: 20208539 doi: 10.1038/ni.1851]
17. Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 2008; 93: 3430-3435 [PMID: 18544622 doi: 10.1210/jc.2008-0241]